AC
CTIC

Avestar Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Avestar Capital’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-600
Closed – – 974
2019
Q2 		$0 Hold
600
– – ﹤0.01% 1021
2019
Q1 		$0 Hold
600
– – ﹤0.01% 1024
2018
Q4 		$0 Hold
600
– – ﹤0.01% 1065
2018
Q3 		$1K Hold
600
– – ﹤0.01% 805
2018
Q2 		$2K Hold
600
– – ﹤0.01% 712
2018
Q1 		$2K Hold
600
– – ﹤0.01% 667
2017
Q4 		$1K Buy
+600
New +$1.76K ﹤0.01% 740

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Avestar Capital's CTIC Position: Q3 2019 in Review

Avestar Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2019, closing a stake of 600 shares.

Avestar Capital first reported a position in CTIC in Q4 2017 and held it in 7 quarters. The position peaked at $2K in Q2 2018. 43 funds tracked by Wall St. Rank hold CTIC as of Q3 2019.

  • Avestar Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 600 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2019.
  • Avestar Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2017 and held it in 7 quarters.
  • Avestar Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $2K in Q2 2018.
  • 43 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.